EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
How EY can help
-
Explore our global insights that look at how you can build confidence in AI, drive exponential value throughout your organization and deliver positive human impact. Learn more.
Read more
The integration of artificial intelligence (AI) into these processes is set to transform the portfolio office. AI’s ability to process complex inputs and analyze unstructured data sets offers a more informed, efficient and strategic approach to drug development decisions. By improving data integrity and accelerating the process, AI has the potential to elevate the portfolio office to a strategic partnership with R&D and corporate leaders.
The AI-powered portfolio office unlocks benefits that allow for better data inputs, digital twin and virtual pipeline analytics, and real-time decision support.